For our first, off the record, interview with Dr. Trozzi, click here.
For part one of this interview discussing the PCR test with Dr. Trozzi, click here.
For part two of this interview discussing COVID vaccines with Dr. Trozzi, click here.
Last year, hydroxychloroquine suddenly became a household word given that several prominent figures, including former U.S. president Donald Trump, began praising the drug as a means of treating COVID-19. Alas, there was no shortage of naysayers who stated that this drug isn’t an effective solution when it comes to the Wuhan virus. So, with 20/20 hindsight, did hydroxychloroquine get a bum rap?
Well, according to veteran physician/whistleblower Dr. Mark Trozzi, the answer is yes.
For starters, hydroxychloroquine is not a new drug; rather, it has been around for some 65 years. And it’s relatively cheap. And in many countries the world over, a consumer can purchase hydroxychloroquine over the counter without a prescription.
In fact, those nations that allow for over-the-counter sales of hydroxychloroquine have far lower COVID-19 death rates than those countries where the drug is not readily available. Dr. Trozzi notes that sub-Saharan Africa is a comparatively poor region, but has a comparatively low COVID-19 mortality rate.
So, the question arises: why wasn’t hydroxychloroquine robustly pursued as a potential cure for COVID-19, and a very affordable one at that? Was it simply because president Trump was such a booster of this drug? Dr. Trozzi thinks this could very well be the reason, meaning that it was petty politics — and perhaps the lobbying of big pharmaceutical companies that were more enamoured with the idea of costly vaccines — that was responsible for hydroxychloroquine hitting a dead end.
How sad, for it looks like there is a far worse and more debilitating virus than COVID-19: namely, Trump Derangement Syndrome.